|1.||Motoi, Noriko: 1 article (01/2015)|
|2.||Takahashi, Shunji: 1 article (01/2015)|
|3.||Nakano, Kenji: 1 article (01/2015)|
|4.||Van Glabbeke, Martine: 1 article (07/2009)|
|5.||Cassier, Philippe: 1 article (07/2009)|
|6.||Dufresne, Armelle: 1 article (07/2009)|
|7.||Chabaud, Sylvie: 1 article (07/2009)|
|8.||Ray-Coquard, Isabelle: 1 article (07/2009)|
|9.||Guastalla, Jean-Paul: 1 article (07/2009)|
|10.||Verweij, Jaap: 1 article (07/2009)|
|1.||Sarcoma (Soft Tissue Sarcoma)
04/30/1989 - "Still today, after 10 years of use, the CYVADIC regimen is very widely employed as a standard treatment for recurrent or metastatic soft tissue sarcomas, although the original positive results have been confirmed only by a few authors. "
05/01/1984 - "Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. "
07/01/2004 - "Our data provide information on the longest duration of follow-up ever reported and suggests that CYVADIC may have a potential role in the adjuvant treatment of early-stage uterine sarcoma."
10/01/1994 - "The CYVADIC combination has enjoyed popular medical support for over a decade in the treatment of soft-tissue sarcomas, and there is much documented evidence in the literature of the relative success of this and related regimens. "
10/01/1994 - "An assessment of the relative importance of the components of CYVADIC in the treatment of soft-tissue sarcomas using regression meta-analysis."
08/01/1997 - "The tumor recurred at the duodenum 7 years later and was completely removed following neoadjuvant CYVADIC. "
08/01/1997 - "The tumor was removed with the right kidney and ureter and a part of the vena cava after 2 courses of CYVADIC. "
03/01/2009 - "The recurrent tumors showed remarkable reduction after the two courses of CYVADIC chemotherapy. "
09/01/1999 - "A recurrent tumor showed remarkable reduction after three courses of CYVADIC chemotherapy. "
01/01/1984 - "Chemotherapy (Cyvadic) was administered in 8 advanced tumors with partial response (always below 50% of the initial tumor) in 5 patients."
|3.||Neoplasm Metastasis (Metastasis)
06/01/1994 - "In contrast, distant metastases occurred with similar frequency in both arms, 32% for CYVADIC versus 36% for control patients (P = .42), and overall survival rates were not significantly different at 63% versus 56% (P = .64). "
09/01/1990 - "Chemotherapy (CyVADic regimen) was attempted in three patients with metastases and one patient with a huge local recurrence, but proved to be ineffective. "
09/01/1994 - "The two-course CYVADIC-etoposide therapy was effective for disseminated pulmonary metastases. "
03/01/2007 - "Resection was done for each metastasis, and postoperative radiotherapy (66 Gy) and chemotherapy (CYVADIC) were done. "
03/01/1980 - "One patient had a complete response and showed no evidence of disease 23 months after treatment with surgery and combination chemotherapy (CYVADIC); she also had maturation of established metastases. "
02/01/1990 - "We treated a patient with a large gastric epithelioid leiomyosarcoma with a combination of surgery and the CYVADIC regime. "
09/01/1999 - "[Remission due to CYVADIC chemotherapy of primary leiomyosarcoma derived from mesentelium of the sigmoid colon: a case report]."
08/01/1989 - "[Successful CYVADIC combination chemotherapy of metastatic pulmonary lesions involving a mediastinal leiomyosarcoma--a case report]."
09/01/1994 - "Uterine myxoid leiomyosarcoma and CYVADIC-etoposide therapy."
09/01/1999 - "We report a case of leiomyosarcoma of mesenthelium origin, which was successfully treated with a combination of cyclophosphamide, vincristine, adriamycin and dacarbazine (CYVADIC). "
01/01/1980 - "CYVADIC toxicity was predominantly limited to myelosuppression, vomiting, fever of unknown origin, and neuropathy. "
10/01/1987 - "A total of 237 cycles of this modified CYVADIC protocol resulted in tolerable toxicity (except nausea and vomiting) and therapeutic results comparable to the original protocol (6/22 complete remissions and 6/22 partial remissions in sarcomas; 1/5 partial remission in mesotheliomas). "
|3.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|4.||Combination Drug Therapy (Combination Chemotherapy)